Delayed
Hong Kong S.E.
04:08:20 2024-05-14 EDT
|
5-day change
|
1st Jan Change
|
0.054
HKD
|
-8.47%
|
|
+35.00%
|
+8.00%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
710.5
|
710.5
|
710.5
|
710.5
|
158.8
|
83.59
|
Enterprise Value (EV)
1 |
564.4
|
624.1
|
647.2
|
573.2
|
5.69
|
-20.07
|
P/E ratio
|
21.4
x
|
-16.1
x
|
-10.2
x
|
-250
x
|
-2.04
x
|
-3.77
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.91
x
|
5.99
x
|
5.33
x
|
2.12
x
|
1.77
x
|
1.67
x
|
EV / Revenue
|
1.52
x
|
5.26
x
|
4.86
x
|
1.71
x
|
0.06
x
|
-0.4
x
|
EV / EBITDA
|
129
x
|
-36.1
x
|
-15.9
x
|
-200
x
|
-0.08
x
|
1.21
x
|
EV / FCF
|
9.38
x
|
52
x
|
-9.03
x
|
-8.21
x
|
0.11
x
|
0.67
x
|
FCF Yield
|
10.7%
|
1.92%
|
-11.1%
|
-12.2%
|
872%
|
150%
|
Price to Book
|
0.98
x
|
1.09
x
|
1.17
x
|
1.12
x
|
0.3
x
|
0.17
x
|
Nbr of stocks (in thousands)
|
1,671,847
|
1,671,847
|
1,671,847
|
1,671,847
|
1,671,847
|
1,671,847
|
Reference price
2 |
0.4250
|
0.4250
|
0.4250
|
0.4250
|
0.0950
|
0.0500
|
Announcement Date
|
19-04-23
|
20-04-23
|
21-04-23
|
22-04-26
|
23-04-27
|
24-04-24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
372.4
|
118.6
|
133.2
|
335.4
|
89.77
|
50.15
|
EBITDA
1 |
4.363
|
-17.29
|
-40.76
|
-2.859
|
-68.46
|
-16.63
|
EBIT
1 |
0.543
|
-21.72
|
-44.89
|
-7.08
|
-73.42
|
-21.42
|
Operating Margin
|
0.15%
|
-18.31%
|
-33.7%
|
-2.11%
|
-81.78%
|
-42.71%
|
Earnings before Tax (EBT)
1 |
39.2
|
-43.79
|
-69.9
|
-3.608
|
-80.29
|
-22.34
|
Net income
1 |
33.2
|
-44.11
|
-69.73
|
-2.824
|
-77.95
|
-22.17
|
Net margin
|
8.92%
|
-37.18%
|
-52.35%
|
-0.84%
|
-86.83%
|
-44.2%
|
EPS
2 |
0.0199
|
-0.0264
|
-0.0417
|
-0.001700
|
-0.0466
|
-0.0133
|
Free Cash Flow
1 |
60.2
|
11.99
|
-71.7
|
-69.84
|
49.6
|
-30.07
|
FCF margin
|
16.16%
|
10.11%
|
-53.82%
|
-20.82%
|
55.25%
|
-59.95%
|
FCF Conversion (EBITDA)
|
1,379.88%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
181.32%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-04-23
|
20-04-23
|
21-04-23
|
22-04-26
|
23-04-27
|
24-04-24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
146
|
86.5
|
63.4
|
137
|
153
|
104
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
60.2
|
12
|
-71.7
|
-69.8
|
49.6
|
-30.1
|
ROE (net income / shareholders' equity)
|
4.57%
|
-6.39%
|
-11.1%
|
-0.46%
|
-13.5%
|
-4.41%
|
ROA (Net income/ Total Assets)
|
0.04%
|
-1.88%
|
-4.22%
|
-0.67%
|
-7.64%
|
-2.6%
|
Assets
1 |
78,311
|
2,351
|
1,652
|
418.7
|
1,021
|
853.9
|
Book Value Per Share
2 |
0.4300
|
0.3900
|
0.3600
|
0.3800
|
0.3100
|
0.2900
|
Cash Flow per Share
2 |
0.0900
|
0.0500
|
0.0400
|
0.0900
|
0.0900
|
0.0600
|
Capex
1 |
8.18
|
1.18
|
0.26
|
0.06
|
8.7
|
0.04
|
Capex / Sales
|
2.2%
|
0.99%
|
0.2%
|
0.02%
|
9.69%
|
0.09%
|
Announcement Date
|
19-04-23
|
20-04-23
|
21-04-23
|
22-04-26
|
23-04-27
|
24-04-24
|
|
1st Jan change
|
Capi.
|
---|
| +8.00% | 12.63M | | -29.72% | 15.63B | | -22.89% | 12.43B | | -24.53% | 6.57B | | +15.23% | 6.46B | | -12.21% | 6.04B | | -1.90% | 4.63B | | +62.00% | 4.61B | | -5.94% | 3.94B | | -9.36% | 3.51B |
Other Drug Retailers
|